Not known Factual Statements About ABBV-744 preclinical studies and results
In Phase C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Contributors will obtain treatment until sickness progression or even the members are unable to tolerate the study drugs.after which endorse H3K27Ac at this region. Chromatin hyperacetylation could improve the accessibility